Clinical Trials Using Alpelisib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Alpelisib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments
Location: 15 locations
Phase I / Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.
Location: 6 locations
Alpelisib in Treating Participants with Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Alpelisib and Enzalutamide in Treating Patients with Androgen Receptor and PTEN Positive Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of alpelisib when given together with enzalutamide in treating patients with androgen receptor and PTEN positive breast cancer that has spread to other places in the body. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgen receptor can cause the growth of breast cancer cells. Hormone therapy using enzalutamide may fight breast cancer by lowering the amount of androgen the body makes. Giving alpelisib and enzalutamide may work better in treating patients with breast cancer.
Location: M D Anderson Cancer Center, Houston, Texas
Alpelisib, Cetuximab, and Cisplatin in Treating Patients with HPV-Associated Oropharyngeal Cancer That Can Be Removed by Surgery
This phase I / II trial studies the side effects and best way to give alpelisib, cetuximab, and cisplatin and to see how well these drugs work in treating patients with human papillomavirus (HPV)-associated oropharyngeal cancer that can be removed by surgery. Drugs used in chemotherapy, such as alpelisib and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving alpelisib, cisplatin, and cetuximab together may kill more tumor cells.
Location: 5 locations
Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of buparlisib or alpelisib when given together with olaparib in treating patients with triple negative breast cancer or high grade serous ovarian cancer that has come back (recurrent). Buparlisib, alpelisib, and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: See Clinical Trials.gov